The stock's fall snapped a four-day winning streak.

This was the stock's fourth consecutive day of gains.

In a report released today, Paul Matteis from Stifel Nicolaus maintained a Buy rating on Alto Neuroscience, Inc. (ANRO – Research Report), with ...

U.S. stock futures rose on Monday after Friday’s sharp fall as investors digested the tariff updates and earnings reports.

CPI Readings Due in U.S. Next Week Monday U.S. Featured Earnings McDonalds (NYSE:MCD) (Q4) EPS of $2.82 compared to $2.95 in ...

Below is Validea's guru fundamental report for VERTEX PHARMACEUTICALS INC (VRTX). Of the 22 guru strategies we follow, VRTX rates highest using our P/B Growth Investor model based on the published ...

Precision medicine is revolutionizing healthcare, and these genomic stocks are leading the way. Therefore, as this sector ...

The first shot taken at Medicaid, likely UnitedHealthcare coverage for Vertex's pain drug, and Optum’s wellness visit ad.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

and Orna Therapeutics (through its wholly owned subsidiary ReNAgade Therapeutics Inc.) announced a three-year strategic research collaboration with Vertex Pharmaceuticals Incorporated (Nasdaq ...

Jan. 29, 2025 (GLOBE NEWSWIRE) -- Vertex Inc. (NASDAQ:VERX ... Not to be confused with Vertex Pharmaceuticals, Vertex is a company specializing in consulting services and tax preparation ...